Tilray Brands/$TLRY
1D1W1MYTD1Y5YMAX
Capital at risk
About Tilray Brands
Tilray is as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. The company portfolio includes brand such as Sweet Water Brewing, Montauk Brewing, Brew Dog, Shock Top, 10 Barrell, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest and Hi-Ball. The company has four segment Beverage, Cannabis, Distribution and Wellness. The majority of the revenue is generated from Distribution business which encompasses the purchase and resale of pharmaceuticals products to customers.
- Ticker
- $TLRY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,595
- Headquarters
- Leamington, Canada
- Website
- www.tilray.com
Tilray Brands Metrics
BasicAdvanced
$551M
-
-$1.09
1.92
-
Price and volume
Market cap
$551M
Beta
1.92
52-week high
$15.70
52-week low
$3.67
Average daily volume
3.9M
Financial strength
Current ratio
2.21
Quick ratio
1.173
Long term debt to equity
0.225
Total debt to equity
0.25
Interest coverage (TTM)
-1.76%
Profitability
EBITDA (TTM)
14.999
Gross margin (TTM)
28.68%
Net profit margin (TTM)
-13.26%
Operating margin (TTM)
-5.75%
Effective tax rate (TTM)
-19.42%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-1.49%
Return on equity (TTM)
-6.82%
Valuation
Price to revenue (TTM)
0.491
Price to book
0.33
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-4.402
Free cash flow yield (TTM)
-22.72%
Free cash flow per share (TTM)
-0.913
Growth
Revenue change (TTM)
11.46%
Earnings per share change (TTM)
-95.56%
3-year revenue growth (CAGR)
13.44%
10-year revenue growth (CAGR)
65.01%
3-year earnings per share growth (CAGR)
-64.07%
10-year earnings per share growth (CAGR)
36.26%
Bulls say / Bears say
International medical cannabis revenue rose 34% in fiscal 2026, with strong growth in Germany, the UK, Poland and Italy. This gives Tilray a faster-growing business beyond Canada’s mature market. (GlobeNewswire, Tilray Brands)
Tilray improved its financial position materially: fiscal 2026 adjusted EBITDA reached $61.1 million, cash and marketable securities were about $235 million, and net debt fell to roughly $0.7 million. Management is guiding for adjusted EBITDA of $68 million to $75 million in fiscal 2027. (GlobeNewswire, Tilray Brands)
US cannabis rescheduling could open a route into a regulated medical market, where Tilray already has international medical infrastructure and experience. The process remains active after a federal appeals court declined to pause it, preserving a potential regulatory catalyst. (Tilray Brands, The Motley Fool)
Tilray remains loss-making on a GAAP basis, reporting a $105.2 million fiscal 2026 net loss. Adjusted free cash flow was still negative, so the improved EBITDA has not yet translated into sustainable cash generation. (GlobeNewswire, Yahoo Finance)
The beverage segment’s fiscal 2026 revenue growth came with weaker economics: gross profit fell 2% and gross margin dropped to 36% from 39%. This raises questions about whether the BrewDog expansion and other beverage acquisitions can create value rather than add integration and cost pressure. (Tilray Brands, GlobeNewswire)
Tilray has relied on equity transactions to reduce debt, including a recent exchange of $12 million of convertible notes for 2.84 million new shares. That lowers near-term debt risk but dilutes existing shareholders and may limit per-share gains from future operating improvements. (TipRanks.com, Roic AI)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Upcoming events
No upcoming events
Tilray Brands News
AllArticlesVideos
Funds containing Tilray Brands
AllEURGBPUSD
Fund name | Fund size | $TLRY weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.